Bones Home > Jakafi

Jakafi is a medicine licensed for the treatment of a certain type bone marrow disorder called myelofibrosis. It is designed to help reduce the size of an enlarged spleen and relieve symptoms of myelofibrosis, such as night sweats and bone pain. This medicine comes as a tablet that is taken twice daily. Potential side effects include dizziness, headaches, and bruising.

What Is Jakafi?

Jakafi™ (ruxolitinib) is a prescription medication approved to treat a disorder of the bone marrow known as myelofibrosis. Myelofibrosis is characterized by scarring of the bone marrow. Jakafi is used to treat people who are considered intermediate-risk or high-risk, based on their expected survival. It belongs to a class of medicines known as kinase inhibitors.
 
(Click Jakafi Uses for more information on this topic, including possible off-label uses.)
 

Who Makes This Medication?

Jakafi is made by DSM Pharmaceuticals, Inc., for Incyte Corporation.
 

How Does Jakafi Work?

Jakafi works by blocking two enzymes in the body known as janus-associated kinase 1 (JAK1) and 2 (JAK2). These two enzymes help control the formation of blood cells. Myelofibrosis is associated with abnormal activity of JAK1 and JAK2, which causes blood cells to be made in organs such as the spleen. This, in turn, leads to enlargement of the spleen.
 
By inhibiting the action of the abnormal JAK1 and JAK2 enzymes, Jakafi can help reduce spleen size and subsequent symptoms of myelofibrosis.
 

Clinical Effects

Clinical studies have been done to determine the effectiveness of Jakafi in people with myelofibrosis who had enlarged spleens and needed treatment because of symptoms. In these studies, Jakafi was shown to reduce spleen size and relieve myelofibrosis symptoms, including:
 
  • Abdominal (stomach) discomfort
  • Night sweats
  • Itching
  • Bone or muscle pain.
 
In these studies, more people given Jakafi had a 35 percent reduction in the size of their spleen compared to people given a placebo (a "sugar pill" with no active ingredients) or other best available treatments. In addition, more people given Jakafi had at least a 50 percent reduction in their symptoms, compared to people given the placebo.
 
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation
Advertisement


Topics & Medications

Quicklinks

Related Channels

eMedTV Links
Copyright © 2006-2017 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.